VivoSim Labs, INC. (VIVS) Form 8-K Material Events
VivoSim Labs, INC. (VIVS) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: VIVS
CIK: 1497253
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 03/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Rosenberg Rich Baker Berman, P.A.
Auditor SinceSince 3/31/2024 12:00:00 AM
Lead Engagement PartnerRobert Quick
Audit LocationSomerset, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-16 | 2026-10-13 | 8-K | 0001193125-26-424061 | View SEC Doc Filr Page |
| 8-K | 2026-10-06 | 2026-09-30 | 8-K | 0001193125-26-415542 | View SEC Doc Filr Page |
| 4 | 2026-09-01 | 2026-08-31 | 4 | 0001193125-26-378358 | View SEC Doc Filr Page |
| ARS | 2026-08-21 | 2026-03-31 | ARS | 0001193125-26-361092 | View SEC Doc Filr Page |
| 8-K | 2026-08-21 | 2026-08-17 | 8-K | 0001193125-26-361085 | View SEC Doc Filr Page |
| DEF 14A | 2026-08-21 | 2026-09-30 | DEF 14A | 0001193125-26-361066 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-17 | — | SCHEDULE 13G/A Filing | 0001104659-26-098000 | View SEC Doc Filr Page |
| PRER14A | 2026-08-13 | — | PRER14A | 0001193125-26-349548 | View SEC Doc Filr Page |
| 10-Q | 2026-08-12 | 2026-06-30 | 10-Q | 0001193125-26-346820 | View SEC Doc Filr Page |
| EFFECT | 2026-08-10 | — | EFFECT Filing | 9999999995-26-002599 | View SEC Doc Filr Page |
| PRE 14A | 2026-08-10 | 2026-09-30 | PRE 14A | 0001193125-26-341405 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | 8-K | 0001193125-26-336844 | View SEC Doc Filr Page |
| S-1 | 2026-07-31 | — | S-1 | 0001193125-26-328613 | View SEC Doc Filr Page |
| 8-K | 2026-07-30 | 2026-07-30 | 8-K | 0001193125-26-326139 | View SEC Doc Filr Page |
| 8-K | 2026-07-24 | 2026-07-20 | CURRENT REPORT | 0001213900-26-081377 | View SEC Doc Filr Page |
| 8-K | 2026-07-17 | 2026-07-16 | 8-K | 0001193125-26-306849 | View SEC Doc Filr Page |
| 10-K | 2026-07-14 | 2026-03-31 | 10-K | 0001193125-26-303316 | View SEC Doc Filr Page |
| NT 10-K | 2026-06-29 | 2026-03-31 | NT 10-K | 0001193125-26-288413 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-04-06 | — | SCHEDULE 13G Filing | 0001104659-26-039856 | View SEC Doc Filr Page |
| 8-K | 2026-04-03 | 2026-03-31 | 8-K | 0001193125-26-142106 | View SEC Doc Filr Page |
| 424B4 | 2026-04-02 | — | PROSPECTUS | 0001213900-26-039307 | View SEC Doc Filr Page |
| EFFECT | 2026-03-31 | — | EFFECT Filing | 9999999995-26-001032 | View SEC Doc Filr Page |
| CORRESP | 2026-03-31 | — | CORRESP Filing | 0001213900-26-037179 | View SEC Doc Filr Page |
| CORRESP | 2026-03-31 | — | CORRESP Filing | 0001213900-26-037177 | View SEC Doc Filr Page |
| S-1/A | 2026-03-31 | — | AMENDMENT NO. 1 TO FORM S-1 | 0001213900-26-037009 | View SEC Doc Filr Page |